This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Talon Therapeutics, Inc. Reports Fourth Quarter And Year End 2010 Financial Results

SAN MATEO, Calif., March 28, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) today reported financial results for the fourth quarter and full year ended December 31, 2010, and provided a corporate update.

"2010 was a year of significant accomplishments for Talon clinically and financially," stated Steven R. Deitcher, M.D., President and Chief Executive Officer of Talon Therapeutics. "For 2011, we will continue our focus on submitting a New Drug Application for accelerated approval of Marqibo."

2010 Corporate Highlights
  • Completed and presented data for a Phase 2 pivotal study of Marqibo(R) for the treatment of Philadelphia chromosome negative (Ph-) adult acute lymphoblastic leukemia (ALL) in second or greater relapse or that has progressed following two or more prior lines of anti-leukemia therapy, referred to as the rALLy study.
  • Completed the Phase 1 program for Menadione Topical Lotion for the treatment of dose-limiting skin rash associated with taking epidermal growth factor receptor (EGFR) inhibitors for anti-cancer treatment.
  • Completed a financing with Warburg Pincus and Deerfield Management for up to $100 million, of which $40 million was received in June 2010.
  • Strengthened intellectual property coverage with new patents issued for Menadione Topical Lotion and Marqibo.

Three Months Ended December 31, 2010 Unaudited Financial Results

For the three months ended December 31, 2010, the Company reported a net loss of $6.3 million and deemed dividends on preferred stock of $0.9 million, which when combined, resulted in a net loss applicable to common stockholders of $7.2 million, or $0.34 per share. The deemed dividends on preferred stock contributed $0.05 per share to the total net loss applicable to common stockholders for the three months ended December 31, 2010. This compares with a net loss of $5.0 million, or a loss per share of $0.28, for the three months ended December 31, 2009. There were no deemed dividends on preferred stock for the three months ended December 31, 2009.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,751.39 +121.12 0.69%
S&P 500 2,108.57 +15.32 0.73%
NASDAQ 5,111.7330 +22.5270 0.44%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs